QSQiao‐Qiao Shao

Qiao‐Qiao Shao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qiao‐Qiao Shao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Jun‐Bo Zhao

    Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital Zhengzhou Henan China

    2 shared publications
  • Miao Yu

    Department of Gastroenterology, Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou China

    2 shared publications
  • Song-Ze Ding

    Department of Gastroenterology and Hepatology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China

    2 shared publications
  • Bai‐Ling Jia

    Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University and Henan Provincial People’s Hospital Zhengzhou China

    1 shared publication
  • Bai‐Ling Jia

    Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital Zhengzhou Henan China

    1 shared publication
  • Chen Zhang

    Department of Gastroenterology and Hepatology Anyang Municipal People's Hospital Anyang Henan China

    1 shared publication

Latest Publications

  • Both family‐based Helicobacter pylori infection control and management strategy and screen‐and‐treat strategy are cost‐effective for gastric cancer prevention

    by Jing Ma, Miao Yu, Qiao‐Qiao Shao, Xue‐Chun Yu, Chen Zhang, Jun‐Bo Zhao, Lin Yuan, Ya‐Bin Qi, Ruo‐Bing Hu, Pei‐Ru Wei, et al.

    Background: Helicobacter pylori (H. pylori) infection and its related diseases are substantial public health burden for highly infected areas. Recently, a novel family‐based H. pylori infection control and management (FBCM) strategy is introduced for H. pylori infection prevention and control. However, its cost‐effectiveness has not been evaluated. We conducted this health economic evaluation to investigate the cost‐effectiveness of FBCM, screen‐and‐treat, and no‐screen strategies in Chinese population.Materials and Methods: Cost‐effectiveness analysis was performed using decision tree and Markov model. Parameters required for the model were from published literatures and public databases, including health state utility, screening characteristics, treatment effectiveness, and medical costs for the three strategies. Outcomes were cost, quality‐adjusted life year (QALY), incremental cost‐effectiveness ratio (ICER). Uncertainty analysis was performed to verify the robustness of this model.Results: To prevent gastric cancer in a cohort of 1 million asymptomatic Chinese families, FBCM and screen‐and‐treat strategies prevented 1010 and 1201 new gastric cancer cases, reduced 2809 and 3339 gastric cancer‐related death, and saved 956,971 and 1,137,549 QALYs, respectively, when compared with no‐screen strategy. Cost‐effectiveness analysis showed that FBCM strategy cost $9.18/QALY, and screen‐and‐treat strategy cost $12.08/QALY for gastric cancer prevention when compared with no‐screen strategy. One‐way sensitivity analysis revealed that screening from younger age by both strategies are more cost‐effective. When compared with FBCM strategy, screen‐and‐treat strategy saved 5.98% gastric cancer cases and 5.78% of gastric cancer deaths, but costed $9348 to reduce a gastric cancer case. Results are not sensitive to any variables, and probabilistic sensitivity analysis confirmed robustness of the results.Conclusions: Both FBCM and screen‐and‐treat strategies are cost‐effective for gastric cancer prevention compared with no‐screen strategy. Since FBCM is more practical and convenient, it may be an efficient and excellent cost‐effective strategy for gastric cancer prevention in H. pylori and gastric cancer prevalent areas.


  • Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial

    by Qiao‐Qiao Shao, Xue‐Chun Yu, Miao Yu, Jing Ma, Jun‐Bo Zhao, Lin Yuan, Ya‐Bin Qi, Ruo‐Bing Hu, Pei‐Ru Wei, Wei Xiao, et al.

    Background: Antibiotic resistance emerges as a major issue for Helicobacter pylori (H. pylori) treatment. High‐dose dual therapy has recently shown encouraging results in H. pylori eradication, but it has yet to be validated in this H. pylori highly infected area; it is also not known if this concept can be extended to antibiotics other than amoxicillin, and factors that affect the eradication. We investigate if rabeprazole plus amoxicillin or furazolidone regimens could be a first‐line therapy for H. pylori eradication, and factors that affect the curing rate.Methods: This is a single‐center, prospective, open‐label, randomized‐controlled trial. Naive patients (n=292) were randomly treated with bismuth‐containing quadruple therapy (BQT), rabeprazole plus amoxicillin (RADT), or furazolidone (RFDT) groups. RADT and FADT use three times daily regimens. H. pylori diagnosis and eradication were determined and confirmed by 13C‐urea breath test.Results: In per‐protocol (PP) analysis, H. pylori eradication rate was 91.2% in BQT group, 89.6% in RADT, and 51.0% in RFDT group. In intention‐to‐treat (ITT) analysis, infection was eradicated in 86.7% of patients in BQT group, 85.8% in RADT, and 48.1% in RFDT groups, respectively. Noninferiority was confirmed between BQT and RADT groups. The incidence of side effects in BQT group was significantly higher than that in RADT group. Successful eradication was associated with lower body surface area (BSA) and low body mass index (BMI) in BQT group. Smoking and high BSA index reduced H. pylori eradication rate in RADT group.Conclusions: Rabeprazole‐amoxicillin dual therapy is equally effective to the bismuth‐containing quadruple therapy for H. pylori eradication with fewer side effects and saves use of one antibiotic per each treatment. Successful eradication is also associated with low BSA and non‐smoking condition, which deserves future stratified analysis for refinement and optimization.